Abstract:Background Intrahepatic cholangiocarcinoma (ICC) exhibits a very low response rate to immune checkpoint inhibitors (ICIs) and the underlying mechanism is largely unknown. We investigate the tumor immune microenvironment (TIME) of ICCs and the underlying regulatory mechanisms with the aim of developing a new target to inhibit tumor growth and improve anti-PD-1 efficacy. Methods Tumor tissues from ICC patients together with hydrodynamic ICC mouse models were employed to identify the key cell population in TIME of ICCs. Functional analysis and mechanism studies were performed using cell culture, condition knockout mouse model and hydrodynamic transfection ICC model. The efficacy of single or combined therapy with anti-PD-1 antibody, gene knockout and chemical inhibitor were evaluated in vivo. Results Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are enriched in advanced ICCs and significantly correlated with N7-methylguanosine (m7G) tRNA methyltransferase METTL1 (IDDF2022-ABS-0068 Figure 1. PMN-MDSCs are significantly increased in advanced ICC and associated with METTL1 expression. (A) The enrichment score of each TIME infiltrating cell in early-stage (n=30) and late-stage (n=29) ICC tissues. The upper and lower ends of boxes represented interquartile range of values. The black dotes represented outliers and the lines in the boxes showed median value. (B) Representative flow cytometry dot plots of CD33+CD11b+HLA-DR- MDSC, CD33+CD11b+HLA-DR-CD15+ PMN-MDSC and CD33+CD11b+HLA-DR-CD14+ M-MDSC within CD45+ cells in human ICC tumor tissues. (C) Percentage of MDSC (left panel), PMN-MDSC (middle panel), and M-MDSC (right panel) in early-stage and late-stage or recurrence tumor infiltrating CD45+ immune cells (n=4). (D) Gene-set enrichment analysis identified metabolism of RNA signature was positive correlated with MDSC infiltration. (E) Correlation between METTL1 expression and MDSC enrichment score in our FAH-SYSU cohort and TCGA cohort). Using diverse in vivo cancer models, we demonstrate the crucial immunomodulator function of METTL1 in regulation of PMN-MDSC accumulation in tumor immune microenvironment (TIME) and ICC progression (IDDF2022-ABS-0068 Figure 2. METTL1-mediated m7G tRNA modification induces PMN-MDSC accumulation in ICC. (A) Representative liver images and statistics of liver weights are shown in Ctrl and cKO mice. (n=10). (B) Percentage and absolute number of PMN-MDSC in the liver of Ctrl and cKO mice tumor infiltrating CD45+ immune cells (n=10). (C) Representative images of Ly6G+ cells in tumors detected by immunohistochemistry (IHC) and statistics of the number of Ly6G+ cells in Ctrl and cKO tumor. (D) Representative liver tumor morphology and statistical analysis of liver weights in oeNC and oeM1 mice (n=6). (E) The percentage and absolute number of PMN-MDSC within CD45+ cells in oeNC and oeM1 mice (n=6). (F) Representative IHC images of Ly6G+ cells and the statistical analysis of the number of Ly6G+ cells in oeNC and oeM1 tumors (n=6)). Mechanistically, CXCL8 in humans and Cxcl5 in mice are key translational targets of METTL1 that facilitate its function in promoting PMN-MDSC accumulation in TIME and ICC progression in vivo (IDDF2022-ABS-0068 Figure 3. PMN-MDSC accumulaton is regulated by the m7G tRNA modification-mediated translation control of CXCL8 in human ICC cell lines. (A) GSEA analysis identified the translation efficiency of chemokine signaling pathway was down-regulated in the METTL1 knockout RBE and HuCCT1 cell lines. (B) Screening strategy showing 20 overlapped genes were affected by METTL1 knockout in RBE and HuCCT1 cell lines. (C) 20 overlapped genes were ranked according to their mRNA m7G related codon frequency. (D) Western blot confirmation of METTL1 overexpression and northwestern blot validation of increased tRNA m7G modification in RBE cell line. (E) qRT-PCR analysis to evaluate the transcription level (left panel) and translation ratio (right panel) of CXCL8 mRNA in oeNC, oeWT and oeMut RBE cell line. (F) Relative mRNA distribution of the CXCL8 in each ribosome fractions were analyzed by qRT-PCR in oeNC, oeWT and oeMut RBE cell line. (G) Protein levels of CXCL8 in the condition medium cultured with oeNC, oeWT or oeMut RBE cell line. (H) Schematic diagram of in vitro MDSC migration assay. (I) In vitro MDSC migration assay in the presence of CXCL8 recombinant proteins in METTL1 knockout conditioned medium or CXCL8 neutralization antibody in overexpression wild-type METTL1 conditioned medium). Co-blockade of METTL1 and its downstream chemokine pathway enhances the anti-PD-1 efficacy in ICC pre-clinical mouse models (IDDF2022-ABS-0068 Figure 4. METTL1 depletion and CXCR2 inhibition enhances PD-1 blockade efficacy to eradicate ICC.(A) Representative gross images of 7 groups of livers. + means treated with anti-PD-1 antibody or SB225002, while – means treated with anti-IgG antibody or 2% DMSO. (B) Liver weights in 7 groups of mice (n=5). (C) Percentage of PMM-MDSC in mice tumor infiltrating CD45+ immune cells (n=5). (D) A graphical summary. Tumor-intrinsic METTL1 regulate the translation of CXCL8/Cxcl5 to recruit PMN-MDSC which further lead to anti-PD-1 resistance by inhibiting the CD4+ T cell expansion and the antitumor activity of CD4+ and CD8+ T cells. Targeting METTL1 and CXCR2 to block the migration of PMN-MDSC could recover the proliferation and antitumor function of CD4+ and CD8+ T cells, which further improve the efficacy of anti-PD-1 therapy). Conclusions Our data uncover novel mechanisms underlying chemokine regulation and TIME shaping at the layer of mRNA translation level and provide new insights for the development of efficient cancer immunotherapy strategies.

Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy

BET Protein Inhibition Evidently Enhances Sensitivity to PI3K/mTOR Dual Inhibition in Intrahepatic Cholangiocarcinoma

METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

METTL3-mediated m6A modification promotes chemoresistance of intrahepatic cholangiocarcinoma by up-regulating NRF2 to inhibit ferroptosis in cisplatin-resistant cells

Therapeutic effect and transcriptome-methylome characteristics of METTL3 inhibition in liver hepatocellular carcinoma

Targeting Tumour-Intrinsic N7-methylguanosine Trna Modification Inhibits MDSC Recruitment and Improves Anti-Pd-1 Efficacy.

METTL3 Inhibits Antitumor Immunity by Targeting M6a-Bhlhe41-cxcl1/cxcr2 Axis to Promote Colorectal Cancer.

IDDF2024-ABS-0157 Targeting Tumor-Intrinsic METTL5 Reverses Immune Exclusion and Enhances Anti-Pd-1 Therapy Efficacy in Intrahepatic Cholangiocarcinoma

METTL3-mediated m6A modification regulates the polycomb repressive complex 1 (PRC1) components BMI1 and RNF2 in hepatocellular carcinoma cells

RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the M6a-Glut1-mtorc1 Axis and is a Therapeutic Target

METTL3 Enhances Hepatocellular Carcinoma Progression by Regulating Polycomb Repressive Complex 1 (PRC1) Components BMI1 and RNF2

CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m6A) modification

Methyltransferase-like 3 Induces the Development of Cervical Cancer by Enhancing Insulin-Like Growth Factor 2 Mrna-Binding Proteins 3-Mediated Apoptotic Chromatin Condensation Inducer 1 Mrna Stability

IDDF2022-ABS-0068 Targeting Tumor-Intrinsic N7-methylguanosine Trna Modification Inhibits MDSC Recruitment and Improves Anti-Pd-1 Efficacy

METTL5-mediated 18S Rrna M6a Modification Promotes Oncogenic Mrna Translation and Intrahepatic Cholangiocarcinoma Progression.

METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation

m6A-dependent glycolysis enhances colorectal cancer progression

METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy

METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer